Evidence among blood donors for a 30-year-old epidemic of human T lymphotropic virus type II infection in the United States

Journal of Infectious Diseases

Volumn 180, Issue 6, 1999, Pages 1777-1783

  Murphy, Edward L ^a   Watanabe, Kevin ^b   Nass, Catharie C ^d   Ownby, Helen ^d   Williams, Alan ^c   Nemo, George ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WESTAT   (United States)

^c AMERICAN RED CROSS   (United States)

^d AMERICAN RED CROSS BLOOD SERVICES   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY;

ADULT; AGE; ARTICLE; BLOOD DONOR; EPIDEMIC; FEMALE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; SEROPREVALENCE; SEXUAL TRANSMISSION; UNITED STATES;

ADULT; AGE DISTRIBUTION; AGED; BLOOD DONORS; DISEASE OUTBREAKS; FEMALE; HTLV-I ANTIBODIES; HTLV-I INFECTIONS; HTLV-II ANTIBODIES; HTLV-II INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; TIME FACTORS; UNITED STATES;

EID: 0032750925     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315139     Document Type: Article

References (38)

1. 1. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980;77:7415-9.
2. 2. Kalyanaraman VS, Sarngadharan MG, Robert-Guroff MG, et al. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science 1982;218:571-3.
3. 3. Takatsuki K, Matsuoka M, Yamaguchi K. Adult T-cell leukemia in Japan. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13(Suppl 1):S15-9.
4. 4. Murphy EL, Hanchard B, Figueroa JP, Gibbs WN, Goedert JJ, Blattner WA. Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int J Cancer 1989;43: 250-3.
5. 5. Gessain A, Gout O. Chronic myelopathy associated with human T-lymphotropic virus type I (HTLV-I). Ann Intern Med 1992;117:933-46.
6. 6. Murphy EL, Fridey J, Smith JW, et al. High prevalence of HTLV-associated myelopathy in a cohort of HTLV-I and HTLV-II infected blood donors. Neurology 1997;48:315-20.
7. 7. Mochizuki M, Ono A, Ikeda E, et al. HTLV-I uveitis. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13(suppl 1):S50-6.
8. 8. Nishioka K. HTLV-I arthropathy and Sjögren syndrome. J Acquired Immune Defic Syndr Hum Retrovirol 1996; 13(suppl 1):S57-62.
9. 9. Modahl LE, Young K, Varney K, Khayam-Bashi H, Murphy EL. Are injection drug users seropositive for human T-lymphotropic virus type II (HTLV-II) at increased risk for pneumonia, abscess and lymphadenopathy? J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:169-75.
10. 10. Mahieux R, Ibrahim F, Mauclere P, et al. Molecular epidemiology of 58 new African human T-cell leukemia virus type I (HTLV-1) strains: identification of a new and distinct HTLV-1 molecular subtype in Central Africa and in Pygmies. J Virol 1997;71:1317-33.
11. 11. Murphy EL, Figueroa JP, Gibbs WN, et al. Human T-lymphotropic virus type I (HTLV-I) seroprevalence in Jamaica, I: demographic determinants. Am J Epidemiol 1991;133:1114-24.
12. 12. Riedel DA, Evans AS, Saxinger C, Blattner WA. A historical study of human T lymphotropic virus type I transmission in Barbados. J Infect Dis 1989;159:603-9.
13. 13. Maloney EM, Ramirez H, Levin A, Blattner WA. A survey of human T-cell lymphotropic virus type I (HTLV-I) in southwestern Colombia. Int J Cancer 1989;44:419-23.
14. 14. Maeda Y, Furukawa M, Takehara Y, et al. Prevalence of possible adult T-cell leukemia virus-cariers among volunteer blood donors in Japan: a nation-wide study. Int J Cancer 1984;33:717-20.
15. 15. Hall WW, Ishak R, Zhu SW, et al. Human T-lymphotropic virus type II (HTLV-II): epidemiology, molecular properties, and clinical features of infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13(suppl): S204-S14.
16. 16. Khabbaz RE, Onorato IM, Cannon RO, et al. Seroprevalence of HTLV-1 and HTLV-2 among intravenous drug users and persons in clinics for sexually transmitted diseases. N Engl J Med 1992;326:375-80.
17. 17. Calabro ML, Luparello M, Grottola A, et al. Detection of human T-lymphotropic virus type II/b in human immunodeficiency virus type I coinfected persons in southeastern Italy. J Infect Dis 1993; 168:1273-7.
18. 18. Williams AE, Fang CT, Slamon DJ, et al. Seroprevalence and epidemiological correlates of HTLV-I infection in U.S. blood donors. Science 1988;240: 643-6; published erratum appears in Science 1989;244:757.
19. 19. FDA memorandum: Recommendations for the prevention of human immunodeficiency virus (HIV) transmission by blood and blood products. Washington, DC: Center for Biologies Evaluation and Research. Revised April 1992.
20. 20. Murphy EL, Bryzman S, Williams AE, et al. Demographic determinants of hepatitis C virus (HCV) Seroprevalence in United States Blood Donors. JAMA 1996:275:995-1000.
21. 21. Lal RB, Heneine W, Rudolph DL, et al. Synthetic peptide based immuno-assays for distinguishing between human T-cell lymphotropic virus type I and type II infections in seropositive individuals. J Clin Microhiol 1991;29:2253-8.
22. 22. Roberts BD, Foung SKH, Lipka JJ, et al. Evaluation of an immunoblot assay for serological confirmation and differentiation of human T-cell lymphotropic virus type I and IL J Clin Microbiol 1993;31:260-4.
23. 23. Kleinbaum DG, Kupper LL, Morganstern H. Epidemiologic research. Principles and quantitative methods. Belmont, CA: Lifetime Learning Publications, 1982:130-3.
24. 24. Agius G, Biggar RJ, Alexander SS, et al. Human T-lymphotropic virus type I antibody patterns: evidence for difference by age and risk group. J Infect Dis 1988;158:1235-44.
25. 25. Greenblatt JC. Unpublished data from the 1991-92 Household Survey on Drug Abuse. Rockville, MD: Office of Applied Studies, Substance Abuse and Mental Health Services Administration, US Dept. of Health and Human Services, 1994.
26. 26. Lee H, Swanson P, Shorty V, Zack JA, Rosenblatt JD, Chen ISY High rate of HTLV-II infection in seropositive IV drug abusers in New Orleans. Science 1989;244:471-5.
27. 27. Eble BE, Busch MP, Guiltinan AM, Khayam-Bashi H, Murphy EL. Determination of human T-lymphotropic virus type by polymerase chain reaction and correlation with risk factors in northern California blood donors. J Infect Dis 1993;167:954-7.
28. 28. Biggar RJ, Buskell-Bales Z, Yakshe PN, Caussy D. Gridley G, Seeff L. Antibody to human retroviruses among drug users in three East Coast American cities, 1972-1976. J Infect Dis 1991;163:57-63.
29. 29. Agranoff D, Varney K, Khayam-Bashi H, Murphy EL. Seroprevalence of HTLV-I and HTLV-II among emergency room and clinic patients in San Francisco. West J Med 1996; 164:481-5.
30. 30. Williams AE, Thomson RA, Schreiber GB, et al. Estimates of infectious disease risk factors in US blood donors. Retrovirus Epidemiology Donor Study [see comments]. JAMA 1997;277:967-72.
31. 31. Vitek CR, Gracia FI, Giusti R, et al. Evidence for sexual and mother-tochild transmission of human T lymphotropic virus type II among Guaymi Indians, Panama. J Infect Dis 1995;171:1022-6.
32. 32. Ferrer JF Esteban E, Dube S, et al. Endemic infection with human T cell leukemia/lymphoma virus type IIB in Argentinian and Paraguayan indians: epidemiology and molecular characterization. J Infect Dis 1996; 174:944-53.
33. 33. Feigal E, Murphy EL, Vranizan K, et al. HTLV-I/II in intravenous drug users in San Francisco: risk factors associated with seropositivity. J Infect Dis 1991;164:36-42.
34. 34. Briggs NC, Battjes RJ, Cantor KP, et al. Seroprevalence of human T cell lymphotropic virus type II infection, with or without human immunodeficiency virus type I coinfection, among US intravenous drug users. J Infect Dis 1995;172:51-8.
35. 35. Vlahov D, Khabbaz RF, Cohn S, Galai N, Taylor E, Kaplan JE. Incidence and risk factors for human T-lymphotropic virus type II seroconversion among injecting drug users in Baltimore, Maryland, USA. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:89-96.
36. 36. Schreiber GB, Murphy EL, Horton JA, et al. Risk factors for human T-cell lymphotropic viruses types I and II (HTLV-I and -II) in blood donors: Retrovirus Epidemiology Donor Study. J Acq Immun Defic Syndr Hum Retrovirol 1997;14:263-71.
37. 37. Hjelle B, Wilson C, Cyrus S, et al. Human T-cell leukemia virus type II infection frequently goes undetected in contemporary US blood donors. Blood 1993;81:1641-4.
38. 38. Busch MP, Laycock M, Kleinman SH, et al. Accuracy of supplemental testing for human T-lymphotropic virus types I and II in US blood donors. Blood 1994:83:1143-8.